Zorifertinib API, also known by its development code AZD3759, is an orally active, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It has been developed to inhibit EGFR signaling and has a particular research focus on EGFR-mutant non-small cell lung cancer (NSCLC) involving the central nervous system.
Zorifertinib has been designed with high blood-brain-barrier penetration, making it an important compound in research involving EGFR-mutant NSCLC and brain or CNS metastases. Clinical studies have evaluated its systemic and intracranial antitumor activity.
Zorifertinib has the molecular formula C₂₂H₂₃ClFN₅O₃, molecular weight of approximately 459.9 g/mol, and CAS Number 1626387-80-1.
SDP provides sourcing and supply support for Zorifertinib API, subject to product availability, applicable specifications, regulatory requirements and customer requirements.
| Parameter | Details |
|---|---|
| Product Name | Zorifertinib |
| Development Code | AZD3759 |
| CAS Number | 1626387-80-1 |
| Molecular Formula | C₂₂H₂₃ClFN₅O₃ |
| Molecular Weight | 459.9 g/mol |
| PubChem CID | 78209992 |
| ChEMBL ID | CHEMBL3623290 |
| DrugBank ID | DB14795 |
| UNII | 67SX9H68W2 |
| InChIKey | MXDSJQHFFDGFDK-CYBMUJFWSA-N |
| XLogP3-AA | 4.1 |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Topological Polar Surface Area | 79.8 Ų |
These identifiers and calculated physicochemical properties are reported by PubChem.
Zorifertinib is a targeted anticancer compound that inhibits EGFR tyrosine kinase activity. EGFR is an important signaling protein involved in cellular proliferation and survival.
Certain activating EGFR mutations can drive the growth of non-small cell lung cancer. EGFR-TKIs such as Zorifertinib have therefore been investigated for selectively inhibiting EGFR signaling in tumors carrying sensitizing EGFR mutations.
A major area of interest for Zorifertinib is its ability to penetrate the blood-brain barrier, supporting research into treatment of EGFR-mutant NSCLC with CNS involvement.
Zorifertinib acts as an EGFR tyrosine kinase inhibitor.
EGFR activation triggers intracellular signaling pathways involved in cell growth, proliferation and survival. In EGFR-mutant cancers, abnormal EGFR signaling can contribute to uncontrolled tumor growth.
By inhibiting EGFR kinase activity, Zorifertinib can interfere with EGFR-mediated signaling pathways. Its CNS penetration has also made it a subject of research for EGFR-mutant tumors with brain metastases.
Zorifertinib has been investigated for EGFR-mutant non-small cell lung cancer, particularly cancers with sensitizing EGFR mutations.
One of the major research areas for Zorifertinib is NSCLC with central nervous system metastases. Its ability to penetrate the blood-brain barrier has been evaluated in clinical development.
Zorifertinib is also relevant to research involving:
A Phase 3 EVEREST trial reported significantly longer systemic and intracranial progression-free survival with zorifertinib compared with first-generation EGFR-TKIs in the studied population of EGFR-mutant NSCLC patients with CNS metastases.
Use your actual approved Zorifertinib specification/CoA for numerical limits.
| Parameter | Specification |
|---|---|
| Identification | IR & HPLC compliant |
| Assay | As per approved product specification |
| Related Substances | As per approved product specification |
| Loss on Drying | As per approved product specification |
| Residue on Ignition | As per approved product specification |
| Heavy Metals / Elemental Impurities | Complies with applicable specification |
| Residual Solvents | Complies with applicable specification |
| Water Content | As per approved product specification |
| Particle Size | As per applicable specification |
Do not enter assumed numerical limits unless they are available in your actual Zorifertinib specification or CoA.
Depending on product availability and customer requirements, Zorifertinib API supply may be supported by applicable documentation such as:
Zorifertinib API can be supplied in packaging appropriate to the required quantity, product handling requirements and customer specifications.
Customers can contact SDP regarding:
Storage conditions should follow the applicable manufacturer's approved specification and stability information.
Zorifertinib is a small-molecule EGFR tyrosine kinase inhibitor, also known by the development code AZD3759.
The CAS number is 1626387-80-1.
The molecular formula is C₂₂H₂₃ClFN₅O₃.
The molecular weight is approximately 459.9 g/mol.
AZD3759 is the development code for Zorifertinib.
Zorifertinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase.
Zorifertinib has demonstrated high blood-brain-barrier penetration and has therefore been investigated in EGFR-mutant NSCLC patients with CNS metastases.
Zorifertinib has been studied primarily in EGFR-mutant non-small cell lung cancer, including disease involving CNS metastases.
Bulk availability, MOQ, pricing, documentation and lead time depend on current product availability and applicable regulatory requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |